Serplulimab induced toxic epidermal necrolysis in a patient with small cell lung cancer
10.3760/cma.j.cn114015-20230630-00486
- VernacularTitle:斯鲁利单抗致小细胞肺癌患者中毒性表皮坏死松解症
- Author:
Ting YUAN
1
;
Wenhan WENG
;
Yang ZHAO
;
Zhiying YU
Author Information
1. 北京大学人民医院药学部，北京 100044
- Publication Type:Journal Article
- Keywords:
Epidermal necrolysis, toxic;
Small cell lung cancer;
Immune checkpoint inhibitors;
Serplulimab;
Immune-related adverse events
- From:
Adverse Drug Reactions Journal
2024;26(4):254-256
- CountryChina
- Language:Chinese
-
Abstract:
A 52-year-old male patient with small cell lung cancer developed symptoms of systemic skin redness, edema, and blisters of varying sizes in multiple parts of the body (neck, chest, and feet) 10 days after receiving chemotherapy with TC regimen (albumin paclitaxel and carboplatin) combined with serplulimab for immunotherapy. It is suspected to be toxic epidermal necrolysis caused by serplulimab. After discontinuing serplulimab and receiving symptomatic treatments such as methylprednisolone, loratadine, ebastine, and adjuvant topical mucosal protection for 10 days, the dermatitis basically subsided and the ruptured blisters were scabby. The patient switched to anlotinib and did not receive immunotherapy again.
